DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073–86.
Google Scholar
Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025;75:46–67.
Google Scholar
Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
Google Scholar
Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16:29.
Venugopal S, Sekeres MA. Contemporary management of acute myeloid leukemia: a review. JAMA Oncol. 2024;10:1417–25.
Google Scholar
Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100:860–91.
Google Scholar
Turkalj S, Radtke FA, Vyas P. An overview of targeted therapies in acute myeloid leukemia. Hemasphere. 2023;7:e914.
Google Scholar
Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21:66.
Google Scholar
Moore CG, Stein A, Fathi AT, Pullarkat V. Treatment of relapsed/refractory AML: novel treatment options including immunotherapy. Am J Hematol. 2025;100:23–37.
Google Scholar
Bester AC, Lee JD, Chavez A, Lee YR, Nachmani D, Vora S, et al. An integrated genome-wide CRISPRa approach to functionalize lncRNAs in drug resistance. Cell. 2018;173:649–64.e20.
Google Scholar
Watkins PA, Maiguel D, Jia Z, Pevsner J. Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome. J Lipid Res. 2007;48:2736–50.
Google Scholar
Zhu Y, Yan W, Tong L, Yang J, Ge S, Fan J, et al. Metabolic reprogramming: a crucial contributor to anticancer drug resistance. MedComm. 2025;6:e70358.
Google Scholar
Dembitz V, James SC, Gallipoli P. Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities. Leukemia. 2025;39:1814–23.
Google Scholar
Jones CL, Stevens BM, D’Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34:724.e4.
van Gastel N, Spinelli JB, Sharda A, Schajnovitz A, Baryawno N, Rhee C, et al. Induction of a timed metabolic collapse to overcome cancer chemoresistance. Cell Metab. 2020;32:391–403.e6.
Google Scholar
Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96:1792–8.
Google Scholar
Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108:353–66.
Google Scholar
Song Y, Liu J, Zhao K, Gao L, Zhao J. Cholesterol-induced toxicity: an integrated view of the role of cholesterol in multiple diseases. Cell Metab. 2021;33:1911–25.
Google Scholar
Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148:1145–59.
Google Scholar
Shen WK, Chen SY, Gan ZQ, Zhang YZ, Yue T, Chen MM, et al. AnimalTFDB 4.0: a comprehensive animal transcription factor database updated with variation and expression annotations. Nucleic Acids Res. 2023;51:D39–D45.
Google Scholar
Castro-Mondragon JA, Riudavets-Puig R, Rauluseviciute I, Lemma RB, Turchi L, Blanc-Mathieu R, et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2022;50:D165–D73.
Google Scholar
Kolmykov S, Yevshin I, Kulyashov M, Sharipov R, Kondrakhin Y, Makeev VJ, et al. GTRD: an integrated view of transcription regulation. Nucleic Acids Res. 2021;49:D104–D11.
Google Scholar
Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology – divergent pathophysiology. Nat Rev Endocrinol. 2017;13:710–30.
Google Scholar
He Y, Qi S, Chen L, Zhu J, Liang L, Chen X, et al. The roles and mechanisms of SREBP1 in cancer development and drug response. Genes Dis. 2024;11:100987.
Google Scholar
Lao M, Zhang X, Li Z, Sun K, Yang H, Wang S, et al. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Cancer Commun. 2025;45:1010–37.
Google Scholar
Wei G, Huang Y, Li W, Xie Y, Zhang D, Niu Y, et al. SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance. Cell Death Discov. 2025;11:75.
Google Scholar
Zhao Z, Liu M, Xu Z, Cai Y, Peng B, Liang Q, et al. Identification of ACSF gene family as therapeutic targets and immune-associated biomarkers in hepatocellular carcinoma. Aging. 2022;14:7926–40.
Google Scholar
Song Y, Tian S, Zhang P, Zhang N, Shen Y, Deng J. Construction and validation of a novel ferroptosis-related prognostic model for acute myeloid leukemia. Front Genet. 2021;12:708699.
Google Scholar
Wang M, Su Y, Hou C, Ren K, Liu X, Zhao S, et al. Targeted lipidomics analysis of lysine 179 acetylation of ACSF2 in rat hepatic stellate cells. Prostaglandins Other Lipid Mediat. 2022;163:106671.
Google Scholar
Shi H, Qi H, Xie D, Zhuang J, Qi H, Dai Y, et al. Inhibition of ACSF2 protects against renal ischemia/reperfusion injury via mediating mitophagy in proximal tubular cells. Free Radic Biol Med. 2023;198:68–82.
Google Scholar
Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607–32.
Google Scholar
Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E, et al. Quantitative single-cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia. 2005;19:1543–9.
Google Scholar
Lunghi P, Tabilio A, Dall’Aglio PP, Ridolo E, Carlo-Stella C, Pelicci PG, et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia. 2003;17:1783–93.
Google Scholar
Morita K, Masamoto Y, Kataoka K, Koya J, Kagoya Y, Yashiroda H, et al. BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4. Leukemia. 2015;29:2248–56.
Google Scholar
Pang Y, Zhao Y, Wang Y, Wang X, Wang R, Liu N, et al. TNFAIP8 promotes AML chemoresistance by activating the ERK signaling pathway through interaction with Rac1. J Exp Clin Cancer Res. 2020;39:158.
Google Scholar
Jin Q, Qi D, Zhang M, Qu H, Dong Y, Sun M, et al. CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation. Cell Mol Biol Lett. 2024;29:112.
Google Scholar
Yin F, Yang J, Luo H, Yu T, Lu W, Zhao M, et al. Targeting oncogenic activation of FLT3/SREBP/FASN promotes the therapeutic effect of quizartinib involving disruption of mitochondrial phospholipids. Cell Death Dis. 2025;16:327.
Google Scholar
